TY - JOUR
T1 - Studies on multiple-resistant Staphylococcus aureus. (VIII). Effective combined regimen of arbekacin plus cefuzonam in respiratory infections and sepsis caused by methicillin-resistant Staphylococcus aureus
AU - Watanabe, Akira
AU - Nakai, Yushi
AU - Honda, Yoshihiro
AU - Narumi, Akira
AU - Motomiya, Masakichi
AU - Honma, Mitsunobu
AU - Nishimura, Shigeki
AU - Onodera, Akihiko
AU - Asakura, Kenichi
AU - Yazaki, Kenji
AU - Sato, Kazuo
AU - Baba, Kenji
AU - Kashiwagi, Makoto
AU - Aso, Noboru
AU - Nagai, Kosaku
AU - Nakagawa, Jun
AU - Arai, Hideo
AU - Sasaki, Harukuni
AU - Anzai, Yoshiyuki
AU - Niizuma, Kazunao
AU - Takizawa, Shigeo
AU - Yanase, Kenji
AU - Nakamura, Mikae
AU - Oizumi, Kotaro
AU - Ichikawa, Yoichiro
AU - Tokunaga, Naoto
AU - Kawayama, Tomotaka
AU - Kawahara, Masashi
AU - Ishii, Kozo
AU - Akashi, Atsuhiro
AU - Matumoto, Hisami
AU - Ouchi, Kazuhiro
AU - Higuchi, Tohru
AU - Inoue, Matsuhisa
PY - 1994
Y1 - 1994
N2 - A combined regimen of arbekacin (200 mg/day) plus cefuzonam (2g/day) was continued for 14.5 days (mean) in 29 cases of infection caused by methicillin-resistant Staphylococcus aureus (MRSA) consisting of 19 cases of pneumonia, four cases each of chronic respiratory infection and lung cancer plus infection, and two cases of sepsis, and the therapeutic efficacy, bacteriological efficacy, pharmacokinetics and combined effect of the regimen against isolated MRSA were evaluated. All of the above 29 patients had underlying diseases, of which respiratory diseases and cerebrovascular diseases constituted the majority. MRSA and other species, mostly Pseudomonas aeruginosa, were isolated simultaneously from 9 of the 29 patients. Clinical efficacy was excellent in two patients, good in 22, fair in two and poor in three (efficacy rate: 82.8%). After treatment, 12 strains of MRSA had been eradicated, 10 had decreased and seven persisted. The mean FIC index of the combined regimen against causative MRSA was 0.53. Peak serum concentrations of arbekacin (8.2 μg/ml) and cefuzonam (45.7 μg/ml) were reached at the end of 30 minutes of intravenous drip infusion. The Tl/2 was 130 minutes for arbekacin and 77 minutes for cefuzonam. Safety was evaluated in 37 patients consisting of the 29 above and eight more cases in whom clinical effects could not be evaluated. Transient diarrhea was observed in one patient. Abnormal laboratory data were found in 17 blood samples from 10 patients (27.0%). Four samples exhibited eosinophilia, three elevated γ-GTP, two each elevated GOT, elevated AL-P, elevated BUN and elevated s-creatinine, and one each anemia and elevated T-bilirubin. Such abnormal laboratory data may be attributable to the severity of the underlying diseases. We conclude from the results described above that the combined regimen of cefuzonam plus arbekacin is useful chemotherapy for the treatment of MRSA infections.
AB - A combined regimen of arbekacin (200 mg/day) plus cefuzonam (2g/day) was continued for 14.5 days (mean) in 29 cases of infection caused by methicillin-resistant Staphylococcus aureus (MRSA) consisting of 19 cases of pneumonia, four cases each of chronic respiratory infection and lung cancer plus infection, and two cases of sepsis, and the therapeutic efficacy, bacteriological efficacy, pharmacokinetics and combined effect of the regimen against isolated MRSA were evaluated. All of the above 29 patients had underlying diseases, of which respiratory diseases and cerebrovascular diseases constituted the majority. MRSA and other species, mostly Pseudomonas aeruginosa, were isolated simultaneously from 9 of the 29 patients. Clinical efficacy was excellent in two patients, good in 22, fair in two and poor in three (efficacy rate: 82.8%). After treatment, 12 strains of MRSA had been eradicated, 10 had decreased and seven persisted. The mean FIC index of the combined regimen against causative MRSA was 0.53. Peak serum concentrations of arbekacin (8.2 μg/ml) and cefuzonam (45.7 μg/ml) were reached at the end of 30 minutes of intravenous drip infusion. The Tl/2 was 130 minutes for arbekacin and 77 minutes for cefuzonam. Safety was evaluated in 37 patients consisting of the 29 above and eight more cases in whom clinical effects could not be evaluated. Transient diarrhea was observed in one patient. Abnormal laboratory data were found in 17 blood samples from 10 patients (27.0%). Four samples exhibited eosinophilia, three elevated γ-GTP, two each elevated GOT, elevated AL-P, elevated BUN and elevated s-creatinine, and one each anemia and elevated T-bilirubin. Such abnormal laboratory data may be attributable to the severity of the underlying diseases. We conclude from the results described above that the combined regimen of cefuzonam plus arbekacin is useful chemotherapy for the treatment of MRSA infections.
UR - http://www.scopus.com/inward/record.url?scp=0028215932&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028215932&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.42.26
DO - 10.11250/chemotherapy1953.42.26
M3 - Article
AN - SCOPUS:0028215932
VL - 42
SP - 26
EP - 36
JO - CHEMOTHERAPY
JF - CHEMOTHERAPY
SN - 0009-3165
IS - 1
ER -
